NCT06276491View on ClinicalTrials.gov

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Ovarian CancerEndometrial CancerGerm Cell TumorTesticular Germ Cell TumorOvarian Germ Cell Tumor
Interventions
BIOLOGICAL

XmAb541

Monoclonal bispecific antibody

Trial Locations (9)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

10461

RECRUITING

Montefiore Einstein Comprehensive Cancer Center, The Bronx

22903

RECRUITING

University of Virginia, Charlottesville

30322

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

37203

RECRUITING

SCRI Oncology Partners, Nashville

43210

RECRUITING

The Ohio State University, Columbus

48201

RECRUITING

Karmanos Cancer Institute, Detroit

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

07601

RECRUITING

The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Xencor, Inc.

INDUSTRY